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Abstract
We reported a 23 years old male with chronic hepatitis C virus infection, discontinued from pegylated interferon/
ribavirin combination therapy due to a lack of early virological response. He has developed activation of occult
hepatitis B virus that was successfully treated by a one year of lamivudine therapy.
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Background
Occult hepatitis B virus infection (OBI) is defined as the
presence of hepatitis B virus (HBV) DNA, in serum
and/or the liver tissue without detectable HBsAg with
or without anti-HBc or anti-HBs outside the pre-sero-
conversion window period [1]. In chronic hepatitis C
virus (HCV) infection, the presence of OBI has been
associated with liver enzymes flare [2], increased severity
of liver disease towards advanced fibrosis and cirrhosis
[3], poor response to standard interferon-alpha in many
[3,4], but not all [5] studies, and increased risk of hepa-
tocellular carcinoma [6]. Concerning response to inter-
feron therapy in chronic HCV a previous study by the
first author found OBI to be a statistically non signifi-
cant cause of interferon non-response [7].
Case presentation
A 23 years old male patient with chronic HCV (discov-
ered on a pre-employment checkup 2 years ago) was a
candidate for the combination therapy (pegylated inter-
feron/ribavirin) according to the guidelines of the
National Committee for Control and Prevention of viral
Hepatitis “C” in Egypt. He was not operated upon apart
from circumcision; also he did not receive blood or
blood product transfusion. He had no chronic medical
diseases. His BMI was 27.5 and a liver biopsy score of
A2 F2 (Metavir) without steatosis. His laboratory para-
meters are shown in table 1. Treatment schedule
included pegylated interferon a 2a 180 ug/week (Peg-
feron, Roche, Switzerland) and ribavirin 1000 mg/day
(Virin, Segma, Egypt). At week 12 of therapy he had his
HCV RNA higher than the base line value (lack of early
virologic response) and hence he was discontinued from
the combination therapy. At that time his laboratory
parameters showed OBI with HBV DNA values > 2000
IU (real time PCR technique with a detection limit of 12
IU, Roche Diagnostics, Switzerland) and a decision to
treat this activation with lamivudine (available, safe,
affordable) was taken. After a period of 6 months the
patient was exposed to both HCV and HBV viral load
assessment, HBV was undetected, while HCV RNA was
decreased in comparison with the previous values. A
decision to continue on lamivudine was taken. Six
months later HBV DNA was assayed and still unde-
tected. Since that time he discontinued lamivudine due
to financial constraints. Six months after this disconti-
nuation he was exposed to HBV and HCV viral load
determination. While HBV was undetected, HCV RNA
level was decreased to 7062 IU/ml.
Discussion
It is not recommended to screen for OBI in chronic
HCV before initiation of antiviral therapy [7] and that is
why we do not routinely perform HBV DNA examina-
tion or serological markers assay [8] before initiation of
antiviral therapy for chronic HCV. So we had only a
baseline HBsAg for this patient. On follow up all serolo-
gical markers remained negative (HBsAg, HBeAg, anti-
HBc, Anti-HBs), this may point for a primary occult
infection in this patient rather than a false occult infec-
tion. In the former a low dose of HBV infection may
occur and establish the lymphatic system and later may * Correspondence: emara_20007@yahoo.com
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tory techniques may not detect an antigenically modified
HBsAg [10].
There is a reciprocal inhibition of replication between
both HBV and HCV, with dominance of HCV inhibitory
effect on HBV replication by its core protein [11], there-
fore HBV may flare up when the HCV virus is treated
[12], and this may explain the slightly high levels of
HBV DNA (> 2000 IU/ml) in this patient. But what is
not completely understood is that this patient is a non-
responder to interferon therapy, however HBV flared
and HCV RNA increased than the base line values. And
also the decrease in HCV RNA levels noticed when
HBV DNA was undetected. This may not favor the reci-
procal inhibition of replication between HBV and HCV
in this case.
Both younger age and lack of biochemical flare (no
increase in serum transaminases) could point to an
immune tolerance state of HBV infection in this patient.
There is no consensus about management of OBI
when HBV DNA levels are low [13], while when HBV
DNA level exceeds 2000 IU [12], treatment may be
introduced. Relying on liver biopsy, evidence of fibrosis
was detected (F2), although it is due to HCV rather
than HBV infection, a decision to treat this patient with
HBV viral load > 2000 IU was taken as the presence of
this OBI may favor progression of this fibrosis towards
cirrhosis. Our patient continued on lamiviudine therapy
for 1 year during this year he had his HBV DNA exami-
nation twice and both were undetected. Due to financial
constraints this patient discontinued lamivudine, 6
months after this we examined for HBV and HCV viral
load, HBV DNA was still undetected and HCV RNA
level was 7062 IU/ml.
In HBeAg negative chronic HBV infection treatment
should be continued until HBsAg clearance. While in
HBeAg positive cases a 6 months treatment period after
HBeAg seroconversion is recommended before disconti-
nuation of therapy [12]. Our patient is negative for all
HBV serological markers and hence no finite duration
for therapy could be planned. HBV DNA clearance thus
may be the therapeutic target in this patient. In our case
a one year treatment with lamivudine seems to be suc-
cessful to treat this seronegative OBI activation, with
HBV DNA clearance is the primary end point.
Conclusions
Check the presence of OBI when HCV therapy fails may
be justifiable. Lamivudine could successfully be used in
the treatment of occult hepatitis B activation.
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Table 1 Laboratory characteristics of the patient
Base
line
Week 12 after
interferon
Six months after
Lamivudine therapy
Twelve months after
lamivudine therapy
Six months after lamivudine
discontinuation
ALT (IU/ml) 19 (12) 54 (30-65) 39 (30-65) 58 (40) 38 (40)
AST (IU/ml) 38 (12) 24 (15-37) 26 (15-37) 46 (40) 27 (40)
HCV RNA
(IU/ml)
4174 14839 8970 Not done 7062
HBsAg Negative Negative Not done Not done Negative
HBeAg Not
done
Negative Not done Not done Negative
HBcAb
Total Not
done
Negative Not done Not done Negative
IgM Not
done
Negative Not done Not done Negative
HBs Ab Not
done
Negative Not done Not done Negative
HBV DNA
(IU/ml)
Not
done
2980 Undetected Undetected Undetected
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